Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

NOD2 inhibits tumorigenesis and increases chemosensitivity of hepatocellular carcinoma by targeting AMPK pathway
Xiaomin Ma, Yumin Qiu, Yanlin Sun, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 3
Open Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
Weiwei Tang, Ziyi Chen, Wenling Zhang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 759
Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy
Yan Zhao, Yani Zhang, Kaiting Wang, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2020) Vol. 1874, Iss. 1, pp. 188391-188391
Open Access | Times Cited: 189
The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma
Kyoko Oura, Asahiro Morishita, Sae Hamaya, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2805-2805
Open Access | Times Cited: 25
AMPK: The Energy Sensor at the Crossroads of Aging and Cancer
Vasudevarao Penugurti, Rajesh Manne, Ling Bai, et al.
Seminars in Cancer Biology (2024) Vol. 106-107, pp. 15-27
Closed Access | Times Cited: 8
Thyroid hormones inhibit tumor progression and enhance the antitumor activity of lenvatinib in hepatocellular carcinoma via reprogramming glucose metabolism
Chun‐Cheng Yang, Yu‐Chuan Yan, Guo‐Qiang Pan, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 1
Therapeutic potential of AMPK signaling targeting in lung cancer: Advances, challenges and future prospects
Milad Ashrafizadeh, Sepideh Mirzaei, Kiavash Hushmandi, et al.
Life Sciences (2021) Vol. 278, pp. 119649-119649
Closed Access | Times Cited: 55
Autophagy, an accomplice or antagonist of drug resistance in HCC?
Yafei Wu, Jigang Zhang, Qin Li
Cell Death and Disease (2021) Vol. 12, Iss. 3
Open Access | Times Cited: 49
MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis
Ting Yu, Jiajian Yu, Lu Lu, et al.
Cellular Oncology (2021) Vol. 44, Iss. 4, pp. 821-834
Open Access | Times Cited: 49
Resistance of Lenvatinib in Hepatocellular Carcinoma
Qiuran Xu, Dong‐Sheng Huang, Jinhui Guo, et al.
Current Cancer Drug Targets (2022) Vol. 22, Iss. 11, pp. 865-878
Closed Access | Times Cited: 27
Upregulation of NOD1 and NOD2 contribute to cancer progression through the positive regulation of tumorigenicity and metastasis in human squamous cervical cancer
Yuanyuan Zhang, Ning Li, Guangwen Yuan, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 24
New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma
Feimu Fan, Joshua S. Fleishman, Chen Jin, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 8, pp. 104069-104069
Closed Access | Times Cited: 5
Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation
Paula Fernández‐Palanca, Tania Payo‐Serafín, Beatriz San‐Miguel, et al.
Acta Pharmacologica Sinica (2022) Vol. 44, Iss. 5, pp. 1066-1082
Open Access | Times Cited: 19
CREB3L4 promotes hepatocellular carcinoma progression and decreases sorafenib chemosensitivity by promoting RHEB-mTORC1 signaling pathway
Zhengchen Jiang, Bowen Shi, Yun Zhang, et al.
iScience (2024) Vol. 27, Iss. 2, pp. 108843-108843
Open Access | Times Cited: 4
Neutrophil-induced pyroptosis promotes survival in patients with hepatoblastoma
Tingyi Fu, Jiquan Zhou, Liyuan Yang, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 3
Open Access
Development of a MVI associated HCC prognostic model through single cell transcriptomic analysis and 101 machine learning algorithms
Jiayi Zhang, Zheng Zhang, C.-G. Yang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
The cancer microbiome
Huapeng Li, Anne A. Leaman, Qingfei Zheng
Advances in clinical chemistry (2025)
Closed Access
Role of AMPK and its molecular intermediates in subjugating cancer survival mechanism
Anand Thirupathi, Yan‐Zhong Chang
Life Sciences (2019) Vol. 227, pp. 30-38
Closed Access | Times Cited: 35
The E3 ubiquitin ligase MG53 inhibits hepatocellular carcinoma by targeting RAC1 signaling
Xiaomin Ma, Xiaoxiao Ma, Lihui Zhu, et al.
Oncogenesis (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 18
HepG2 exosomes coated luteolin nanoparticles remodeling hepatic stellate cells and combination with sorafenib for the treatment of hepatocellular carcinoma
Shengjie Ye, Xier Pan, Linghui Zou, et al.
Cancer Nanotechnology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
<p>Glucometabolic Reprogramming in the Hepatocellular Carcinoma Microenvironment: Cause and Effect</p>
Huining Tian, Xiaoyu Zhu, You Lv, et al.
Cancer Management and Research (2020) Vol. Volume 12, pp. 5957-5974
Open Access | Times Cited: 27
Identification of pyroptosis‐related gene prognostic signature in head and neck squamous cell carcinoma
Zhanzhan Li, Lin Shen, Yanyan Li, et al.
Cancer Medicine (2022) Vol. 11, Iss. 24, pp. 5129-5144
Open Access | Times Cited: 16
Preclinical mouse models of hepatocellular carcinoma: An overview and update
Catherine Yujia Gu, Terence K. Lee
Experimental Cell Research (2022) Vol. 412, Iss. 2, pp. 113042-113042
Open Access | Times Cited: 15
Long Noncoding RNA XIST Promotes Resistance to Lenvatinib in Hepatocellular Carcinoma Cells via Epigenetic Inhibition of NOD2
Anqi Duan, Hui Li, Wenlong Yu, et al.
Journal of Oncology (2022) Vol. 2022, pp. 1-17
Open Access | Times Cited: 15
FOXA2 plays a critical role in hepatocellular carcinoma progression and lenvatinib-associated drug resistance
Zhengxia Wang, Junyi Shen, Chuwen Chen, et al.
BioScience Trends (2023) Vol. 17, Iss. 2, pp. 136-147
Open Access | Times Cited: 9
NOD-like receptors in the pathogenesis of metabolic (dysfunction)-associated fatty liver disease: Therapeutic agents targeting NOD-like receptors
Shaghayegh Khanmohammadi, Bruno Ramos‐Molina, Mohammad Shafi Kuchay
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 7, pp. 102788-102788
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top